Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

Completed · Phase 1

Conditions studied: Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)

In brief

The study is designed to assess the demographic, clinical and imaging associations with the presence of microbleeds in atypical Alzheimer's disease. The primary hypothesis is that cognitive and functional performance will be poorer in atypical Alzheimer's subjects with microbleeds compared to those without microbleeds.

Key facts

Study ID

NCT01723553

Run by

Mayo Clinic

People needed

27

Starts

2012-11-01

Expected to finish

2015-03-01

Last updated by the study team

2015-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• over the age of 21
• will have an informant/study partner who will be able to provide independent evaluation of functioning
• must fulfill clinical diagnostic criteria for atypical AD, and hence should either have a chief complaint of difficulty with language and fulfill criteria for logopenic variant of primary progressive aphasia, or present with visuospatial/perceptual deficits and fulfill criteria for posterior cortical atrophy
• speaks English as their primary language (including bilingual patients whose primary language is English)
• agrees to and is eligible to undergo MRI and PET scanning
• if woman of child bearing age, must agree to pregnancy test no more than 48 hours before the PET scans

You may not qualify if…

• subjects with concurrent illnesses that could account for the presenting syndrome, such as traumatic brain injury, strokes or developmental syndromes
• subjects meeting criteria for another neurodegenerative disease, particularly typical Alzheimer's dementia
• women that are pregnant or post-partum and breast-feeding
• subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, and if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm)
• subjects will also be excluded if they do not have an informant, do not consent to research or do not complete all components of the study (neurological exam, neuropsychometric tests, MRI, PiB PET)

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.